Candriam Luxembourg S.C.A. Has $654,000 Position in Aduro Biotech Inc. (ADRO)
Candriam Luxembourg S.C.A. continued to hold its position in shares of Aduro Biotech Inc. (NASDAQ:ADRO) during the second quarter, according to its most recent disclosure with the SEC. The fund owned 57,837 shares of the company’s stock at the end of the second quarter. Candriam Luxembourg S.C.A.’s holdings in Aduro Biotech were worth $654,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Acadian Asset Management LLC increased its position in shares of Aduro Biotech by 310.2% in the second quarter. Acadian Asset Management LLC now owns 221,028 shares of the company’s stock worth $2,500,000 after buying an additional 167,140 shares during the period. Creative Planning purchased a new position in shares of Aduro Biotech during the second quarter worth about $158,000. First Republic Investment Management Inc. purchased a new position in shares of Aduro Biotech during the first quarter worth about $633,000. A.R.T. Advisors LLC purchased a new position in shares of Aduro Biotech during the first quarter worth about $610,000. Finally, Jacobs Levy Equity Management Inc. purchased a new position in shares of Aduro Biotech during the first quarter worth about $616,000. Hedge funds and other institutional investors own 29.76% of the company’s stock.
Aduro Biotech Inc. (NASDAQ:ADRO) traded down 0.31% during mid-day trading on Friday, hitting $12.73. 168,561 shares of the stock traded hands. The firm’s 50-day moving average is $13.99 and its 200 day moving average is $13.10. Aduro Biotech Inc. has a 52-week low of $7.26 and a 52-week high of $34.95. The firm’s market cap is $824.32 million.
Aduro Biotech (NASDAQ:ADRO) last released its quarterly earnings results on Wednesday, August 3rd. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.21. The business had revenue of $39 million for the quarter, compared to analysts’ expectations of $25.24 million. Aduro Biotech had a negative net margin of 23.69% and a negative return on equity of 9.23%. The company’s revenue for the quarter was up 306.3% on a year-over-year basis. Equities analysts predict that Aduro Biotech Inc. will post ($1.39) EPS for the current fiscal year.
A number of research firms recently issued reports on ADRO. Canaccord Genuity reiterated a “buy” rating and set a $30.00 target price on shares of Aduro Biotech in a research report on Friday, August 5th. Zacks Investment Research downgraded shares of Aduro Biotech from a “hold” rating to a “sell” rating in a report on Monday, July 18th. Finally, Roth Capital restated a “buy” rating and set a $22.00 price objective on shares of Aduro Biotech in a report on Monday, July 11th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $22.00.
In related news, insider Thomas W. Dubensky sold 25,000 shares of Aduro Biotech stock in a transaction on Thursday, September 1st. The shares were sold at an average price of $14.03, for a total value of $350,750.00. Following the sale, the insider now owns 16,407 shares in the company, valued at $230,190.21. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Stephen T. Isaacs sold 27,273 shares of Aduro Biotech stock in a transaction on Monday, October 3rd. The shares were sold at an average price of $12.67, for a total transaction of $345,548.91. Following the completion of the sale, the chief executive officer now owns 129,473 shares in the company, valued at approximately $1,640,422.91. The disclosure for this sale can be found here. 6.50% of the stock is currently owned by corporate insiders.
About Aduro Biotech
Aduro Biotech, Inc is a clinical-stage immunotherapy company. The Company is focused on the discovery, development and commercialization of therapies that transform the treatment of various diseases. The Company has developed approximately three technology platforms, which include Live, Attenuated, Double-Deleted (LADD), Stimulator of Interferon Genes (STING) Pathway Activator and B-select monoclonal antibodies.
Want to see what other hedge funds are holding ADRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aduro Biotech Inc. (NASDAQ:ADRO).
Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.